Physiomics Share Discussion Threads

[the stigologist] 12/8/2020 11:10

Pumas AI retweeted my tweet mentioning Physiomics :-D

[officerdigby] 12/8/2020 10:57

Stig, It's gonna take another couple of years ramping Stto get the share price back after that RNS.But don't worry you have facilitated many placee sales in the recent spike including guaranteed, your recent mentor.

[the stigologist] 12/8/2020 09:49

Interesting Pumas AI launch event today to apply Modelling and Simulation AI to dosing regimens

This area will be massive and we are in key position in this huge growth market

[spacedust] 12/8/2020 09:04

Biggest cunning shtttt ive ever come across. Look what happened to share price last time he sold a massive chunk of his shares at 8p. Only this time he sold even less at 6.5p

[spacedust] 12/8/2020 08:50

I warned everyone about jim the cunning sold out his shares at 8p 2 years ago and now he is selling his 3.5p placing shares he got.

Jim the cunning. Why didnt he use his own money to cover the costs if he thinks 100p......cunning jim ill be buying at 2p

[jusjusjus] 12/8/2020 08:07

the maths don't quite match, he took over £2k more than he needed to!

[mark10101] 12/8/2020 07:50

Owenga, don’t let facts get in the way of the numpties that frequent this board...

[owenga] 12/8/2020 07:38

He could have sold all the options once exercised, but didn't. Obviously thinks they will go higher.

[owenga] 12/8/2020 07:36

Jim simply sold some shares to cover the cost of the options.

[dane1606] 12/8/2020 07:13

He obviously hasn't read the 100p manifesto ...

[coldspring] 12/8/2020 07:11

Seen it many times here but Jim the cunning is still prowling.

[dane1606] 12/8/2020 07:06

Good old Jim reducing his overall holding ...confidence booster or what ?

[the stigologist] 11/8/2020 18:11

From PYC long time partners ICR (Institute of Cancer Research)



DNA damage and cancer

We provided the first conclusive evidence that the basic cause of cancer is damage to DNA. The discovery changed scientific opinion dramatically and marked a turning point for cancer research.

Until that point, scientists had assumed carcinogens caused cancer by acting on proteins, rather than genes.


Research conducted here at The Institute of Cancer Research in the 1950 and 60s provided the first conclusive evidence indicating that damage to DNA is the root cause of cancer.

Cancer cells replicate at an accelerated rate, often ignoring the normal controls on cell division and growth. Proteins within cells regulate growth and division, and were widely assumed to be the targets for cancer-causing chemicals. However, research conducted at the ICR by Professor Philip Lawley and Professor Peter Brookes showed that cancer is caused by damage not to proteins but to DNA.

Mustard gas
Their discovery was made through working on mustard gas – which was known to cause cancer. In 1960, Professors Lawley and Brookes published a paper which showed that mustard gas reacted with both pure DNA and with the DNA of mice when injected into tumours.

In 1964, Professors Lawley and Brookes published their second classic paper. This used radiolabelled poly-aromatic hydrocarbons (PAHs), which are among the chemicals that give cigarettes their cancer-causing properties. They found a direct correlation between a PAH’s ability to induce tumours when applied to mouse skin, and the degree to which it bound to DNA. There was no correlation with the degree to which the PAH bound to proteins. It was this finding that showed that cancer was caused by chemicals damaging DNA rather than proteins.

'A turning point'
This discovery marked a turning point for cancer research, and is the basis of all modern cancer research and treatment. It explains why some cancers can be inherited, enabling people with a particularly high risk of developing certain cancers to be identified. It has also changed the way that scientists search for new cancer drugs, allowing personalised treatments to be developed that target the specific genetic defects in an individual’s cancer.

[davevt] 11/8/2020 16:11

Unfortunately for Stig, pyc just isn't very good at what they do, or don't do enough.

obviously in Stigs eyes they are the world leader..

[albert3591] 11/8/2020 15:43

Another share for crufts,what breed shall we call it stiggy

[the stigologist] 11/8/2020 11:07

What is Quantitative Systems Pharmacology?

Quantitative Systems Pharmacology (QSP) is an exciting discipline within pharmaceutical development that is showing significant interest from our pharmaceutical clients seeking to gain valuable insights to improve their R&D efficiency and productivity.

QSP involves combining mechanistic models with the PK/PD of a therapeutic agent and the large volumes of readily available, quantitative experimental drug data.

Why QSP?

QSP is increasingly used in drug development to guide research and to aid with critical decision-making.

Optimal use of integrated QSP models can:

Assist with target feasibility and selection
Provide insights into Mechanisms of Action (MOA)
Enable scenario analysis and testing of different drug profiles
Help accelerate drug development and the discovery of new drugs

Areas of Focus
At Physiomics, our core capabilities include creating integrated QSP models. We have worked with clients to develop QSP models using generic literature and to create hybrid models by integrating them with our proprietary Virtual TumourTM technology.

Recent examples of our QSP work:

1. Scenario Testing

We identified a published model of interest to our client and coded it up to perform further analysis, such as:

For which parameters is calibration data realistically available
What is the sensitivity of the model to key parameters
How do key output parameters behave over time as other parameters are perturbed.

Example of parameter sensitivity analysis. Optimal level of inhibitions for two targets (x and y axis) for maximum synergy (z axis).

2. Combining Virtual TumourTM with Mechanistic Model

Having identified a relevant literature model for our client, we were able to code it up and hybridize with Virtual TumourTM to assess the following:

How does a complex literature model compare with in-house models or hybrids in predicting TGI

Which model is most biologically plausible given the predicted behaviour of their parameters

Combining Virtual Tumour with a MAPK/ERK pathway model (Kirouac et al 2017).

Why Partner With Us?

At Physiomics, our team of scientific consultants create integrated QSP models and rigorously test them to provide valuable insights for our clients.

Our clients range from global pharmaceuticals to biotech companies and smaller commercial and not-for profit clients.

[albert3591] 11/8/2020 08:31

Davevt...Looks like shoddy like the red thumb.Bless.

[albert3591] 10/8/2020 18:27

Shoddy did

[albert3591] 10/8/2020 17:44

Got to make a groat or two

[thehitman1] 10/8/2020 17:43

still not 17p?, did anyone pay 17p?.

[mark10101] 10/8/2020 16:54

Albert are you high frequency trading this? Seems much more of a buy, wait for the move then sell when happy type of stock.